Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download Supplementary Table 1 Agents that may inhibit
Document related concepts
no text concepts found
Transcript
Supplementary Table 1 Agents that may inhibit angiogenesis by indirect mechanisms of action. Class EGFR/HER inhibitors Phase Marketed/ Phase III Agents Class Cetuximab Panitumumab Pertuzumab Trastuzumab Monoclonal antibodies Gefitinib Erlotinib Small-molecule tyrosine kinase receptor inhibitor mTOR inhibitors Phase III CCI-779 Small molecule mTOR (the mammalian target of rapamycin) kinase inhibitor COX2 inhibitors Marketed Celecoxib Nonsteroidal anti-inflammatory drug PPAR-γ agonists Marketed Rosiglitazone Thiazolidinedione Proteosome inhibitors Marketed Bortezomib Proteasome inhibitor Bisphosphonates Marketed Zoledronic acid Bisphosphonate Cytokines Marketed Interferon alpha Synthetic protein Thalidomide and analogs Marketed/ Phase III Thalidomide, Lenalidomide Immunomodulating sedative Hormone derivatives Phase II 2-Methoxyestradiol Estrogen derivative
Related documents